Geneoscopy CEO Andrew Barnell On Transforming GI Health: RNA-Based Diagnostics, CRC Screening Opportunity, & Platform Potential Ahead

Recorded on 07/09/26 TD Cowen Life Science & Diagnostic Tools analyst Dan Brennan speaks with Geneoscopy CEO Andrew Barnell post TD Cowen's 5th Annual Tools/Dx Revolution Conference to discuss GI healthcare and the future of GI cancer diagnostics, and Geneoscopy's innovations, partnerships, and growth pillars ahead. Geneoscopy is leveraging its proprietary RNA platform to advance colorectal cancer (CRC) screening through ColoSense, a non-invasive FDA-approved and Medicare-covered stool test. Barnell discusses the origins of the company, the scientific rationale behind their platform, recent commercialization milestones including their partnership with LabCorp, and the company's vision to expand beyond CRC into broader GI indications such as inflammatory bowel disease. Barnell also shares perspectives on competitive differentiation, CRC screening adoption drivers, the role of AI in diagnostics, and Geneoscopy's long-term mission to transform the diagnosis, monitoring and management...